Selectively targets RPE while preserving photoreceptors
R:GEN treatment targeting the peripheral area of leakage has shown favorable visual and structural outcomes in chronic CSC patients without causing scotoma.
Resolution of SRF/PED and Safety of the Treatment
Change of best-correct visual acuity (BCVA) (logMAR) in R:GENtreated patients with chronic central serous chorioretinopathy (CSC). Error bars represent standard deviation (SD). The difference of BCVA (logMAR) was statistically significant at 2 and 3 months after SRT. *P<0.05.
Reference: Roh et al. Graefes Arch Clin Exp Ophthalmol (2016). DOI 10.1007/s00417-015-3262-1
R:GEN has been shown to be an effective and safe treatment of clinically significant DME, it shows functional and anatomical improvement or stabilization in 84% of patients.
Reduction of hard exudates and retinal thickness before and 6 months after the treatment
Mean BCVA improved from 43.7 letters (standard deviation,
SD=9.1) at baseline to 46.1 letters (SD=10.5) at the 6-month
follow-up (p=0.02).
Reference: Roider J, Klatt C, Brinkmann R et al. Graefes Arch Clin Exp
Ophthalmol. 2010;248:1263-1272